Overview Dividends

(OM) Outset Medical - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6901451079

Hemodialysis System, Console, Cartridge, Consumables, Data Platform

Health Care Equipment
Market Cap in USD: 60m
IPO / Inception: 2020-09-15
Return 12m vs S&P 500: -82.5%

EPS (Earnings per Share)

EPS (Earnings per Share) of OM over the last years for every Quarter: "2020-12": -0.75, "2021-03": -0.7, "2021-06": -0.66, "2021-09": -0.65, "2021-12": -0.87, "2022-03": -0.78, "2022-06": -0.92, "2022-09": -0.85, "2022-12": -0.86, "2023-03": -0.9, "2023-06": -0.9, "2023-09": -0.71, "2023-12": -0.59, "2024-03": -0.57, "2024-06": -0.47, "2024-09": -5.85, "2024-12": -5.55, "2025-03": -3.24, "2025-06": -0.84, "2025-09": -0.69,
EPS CAGR: 0.94%
EPS Trend: -37.0%
Last SUE: -0.04
Qual. Beats: 0

Revenue

Revenue of OM over the last years for every Quarter: 2020-12: 17.247, 2021-03: 22.916, 2021-06: 25.216, 2021-09: 26.318, 2021-12: 28.152, 2022-03: 30.55, 2022-06: 25.057, 2022-09: 27.761, 2022-12: 32.007, 2023-03: 33.467, 2023-06: 36.04, 2023-09: 30.362, 2023-12: 30.507, 2024-03: 28.168, 2024-06: 27.388, 2024-09: 28.666, 2024-12: 29.467, 2025-03: 29.752, 2025-06: 31.419, 2025-09: 29.431,
Rev. CAGR: 1.19%
Rev. Trend: 8.5%
Last SUE: -0.67
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 111%
Value at Risk 5%th 148%
Relative Tail Risk -19.22%
Reward TTM
Sharpe Ratio -0.86
Alpha -101.41
CAGR/Max DD -0.80
Character TTM
Hurst Exponent 0.558
Beta 1.506
Beta Downside 2.234
Drawdowns 3y
Max DD 99.28%
Mean DD 78.20%
Median DD 92.20%

Description: OM Outset Medical December 29, 2025

Outset Medical, Inc. (NASDAQ: OM) develops and commercializes the Tablo Hemodialysis System-a compact, all-in-one console that integrates water purification, on-demand dialysate production, and cloud-connected software. The company also operates the Tablo Data Ecosystem (TabloHub, MyTablo, and TabloDash) to support patients, clinicians, and internal analytics, and it distributes consumables such as Tablo cartridges in the U.S. market. Founded in 2003 as Home Dialysis Plus and rebranded in 2015, Outset is headquartered in San Jose, California, and classified under the Health Care Equipment sub-industry.

Key industry drivers include a projected 5-6% CAGR in the U.S. dialysis market through 2030, driven by an aging population and rising prevalence of chronic kidney disease. Outset’s 2023 revenue grew ~38% year-over-year to $62 million, reflecting expanding adoption of home-dialysis solutions, while its gross margin hovered around 55%, indicating pricing power despite competitive pressure from Fresenius and DaVita. The company’s cash runway extends into 2025 under current burn rates, but success hinges on scaling manufacturing capacity and securing broader Medicare reimbursement for home-based therapy.

For a data-rich, quantitative view of OM’s valuation dynamics, you may find the ValueRay platform useful.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-87.8m TTM) > 0 and > 6% of Revenue (6% = 7.20m TTM)
FCFTA -0.19 (>2.0%) and ΔFCFTA 23.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 189.8% (prev 203.0%; Δ -13.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.19 (>3.0%) and CFO -53.3m > Net Income -87.8m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 7.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (17.8m) change vs 12m ago 428.2% (target <= -2.0% for YES)
Gross Margin 37.70% (prev 30.97%; Δ 6.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 42.12% (prev 39.17%; Δ 2.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -4.52 (EBITDA TTM -69.7m / Interest Expense TTM 16.3m) >= 6 (WARN >= 3)

Altman Z'' -18.86

(A) 0.82 = (Total Current Assets 265.4m - Total Current Liabilities 37.4m) / Total Assets 277.3m
(B) -4.15 = Retained Earnings (Balance) -1.15b / Total Assets 277.3m
warn (B) unusual magnitude: -4.15 — check mapping/units
(C) -0.26 = EBIT TTM -73.9m / Avg Total Assets 285.1m
(D) -8.54 = Book Value of Equity -1.15b / Total Liabilities 134.9m
Total Rating: -18.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.61

1. Piotroski 1.50pt
2. FCF Yield 46.57%
3. FCF Margin -44.90%
4. Debt/Equity 0.02
5. Debt/Ebitda 0.48
6. ROIC - WACC (= -42.35)%
7. RoE -71.12%
8. Rev. Trend 8.47%
9. EPS Trend -36.98%

What is the price of OM shares?

As of December 31, 2025, the stock is trading at USD 3.62 with a total of 508,753 shares traded.
Over the past week, the price has changed by +9.04%, over one month by -14.22%, over three months by -75.02% and over the past year by -79.37%.

Is OM a buy, sell or hold?

Outset Medical has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy OM.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the OM price?

Issuer Target Up/Down from current
Wallstreet Target Price 13.3 266%
Analysts Target Price 13.3 266%
ValueRay Target Price 1.4 -61.6%

OM Fundamental Data Overview December 27, 2025

Market Cap USD = 59.7m (59.7m USD * 1.0 USD.USD)
P/S = 0.4974
P/B = 0.4311
Beta = 2.023
Revenue TTM = 120.1m USD
EBIT TTM = -73.9m USD
EBITDA TTM = -69.7m USD
Long Term Debt = 95.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.91m USD (from shortTermDebt, last quarter)
Debt = 3.16m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -33.3m USD (from netDebt column, last quarter)
Enterprise Value = -115.8m USD (59.7m + Debt 3.16m - CCE 178.6m)
Interest Coverage Ratio = -4.52 (Ebit TTM -73.9m / Interest Expense TTM 16.3m)
FCF Yield = 46.57% (FCF TTM -53.9m / Enterprise Value -115.8m)
FCF Margin = -44.90% (FCF TTM -53.9m / Revenue TTM 120.1m)
Net Margin = -73.12% (Net Income TTM -87.8m / Revenue TTM 120.1m)
Gross Margin = 37.70% ((Revenue TTM 120.1m - Cost of Revenue TTM 74.8m) / Revenue TTM)
Gross Margin QoQ = 39.38% (prev 37.77%)
Tobins Q-Ratio = -0.42 (set to none) (Enterprise Value -115.8m / Total Assets 277.3m)
Interest Expense / Debt = 110.1% (Interest Expense 3.48m / Debt 3.16m)
Taxrate = -2.32% (negative due to tax credits) (404.0k / -17.4m)
NOPAT = -75.6m (EBIT -73.9m * (1 - -2.32%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 7.09 (Total Current Assets 265.4m / Total Current Liabilities 37.4m)
Debt / Equity = 0.02 (Debt 3.16m / totalStockholderEquity, last quarter 142.4m)
Debt / EBITDA = 0.48 (negative EBITDA) (Net Debt -33.3m / EBITDA -69.7m)
Debt / FCF = 0.62 (negative FCF - burning cash) (Net Debt -33.3m / FCF TTM -53.9m)
Total Stockholder Equity = 123.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.67% (Net Income -87.8m / Total Assets 277.3m)
RoE = -71.12% (Net Income TTM -87.8m / Total Stockholder Equity 123.5m)
RoCE = -33.75% (EBIT -73.9m / Capital Employed (Equity 123.5m + L.T.Debt 95.5m))
RoIC = -31.37% (negative operating profit) (NOPAT -75.6m / Invested Capital 241.0m)
WACC = 10.98% (E(59.7m)/V(62.9m) * Re(11.56%) + (debt cost/tax rate unavailable))
Discount Rate = 11.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 130.4%
Fair Price DCF = unknown (Cash Flow -53.9m)
EPS Correlation: -36.98 | EPS CAGR: 0.94% | SUE: -0.04 | # QB: 0
Revenue Correlation: 8.47 | Revenue CAGR: 1.19% | SUE: -0.67 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.76 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-2.66 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+40.4% | Growth Revenue=+9.1%

Additional Sources for OM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle